Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Belgium-based biopharmaceutical and specialty chemical company UCB has agreed to sell worldwide rights to its anti-haemorrhagic product Somatostatine-UCB to Eumedica.
Subscribe to our email newsletter
Somatostatine-UCB is indicated for the treatment of acute upper gastrointestinal bleeding resulting from gastric and duodenal ulcers and other.
UCB receives a cash consideration of an industry average sales multiple for established products. Further details of the agreement are not disclosed.
The distribution of Somatostatine-UCB will be organized from the new worldwide logistical center of the group in Manage, Belgium.